|
nasopharyngeal carcinoma |
97 |
|
radiotherapy |
33 |
|
randomized controlled trial |
30 |
|
survival |
30 |
|
chemotherapy |
27 |
|
lung cancer |
26 |
|
efficacy |
24 |
|
nasopharyngeal cancer |
20 |
|
chemoradiotherapy |
19 |
|
epidemiology |
19 |
|
prognosis |
19 |
|
late toxicity |
17 |
|
whole-exome sequencing |
16 |
|
adult |
15 |
|
female |
15 |
|
hong kong |
15 |
|
humans |
15 |
|
nasopharyngeal carcinoma (npc) |
15 |
|
tumor microenvironment |
15 |
|
chinese |
14 |
|
epstein-barr virus |
14 |
|
metastasis |
14 |
|
nomogram |
14 |
|
npc |
14 |
|
prognostication |
14 |
|
aerobic exercise |
13 |
|
cancer susceptibility genes |
13 |
|
capecitabine |
13 |
|
early-age onset |
13 |
|
imrt |
13 |
|
middle aged |
13 |
|
mst1r |
13 |
|
aged |
12 |
|
apobec-mediated signature |
12 |
|
cancer |
12 |
|
intensity-modulated radiation therapy |
12 |
|
intensity-modulated radiotherapy |
12 |
|
mind-body intervention |
12 |
|
nf-κb signaling |
12 |
|
non-small cell lung cancer |
12 |
|
somatic mutation landscape |
12 |
|
targeted therapy |
12 |
|
accelerated fractionation |
11 |
|
esophageal squamous cell carcinoma (escc) |
11 |
|
incidence |
11 |
|
nidogen-2 (nid2) |
11 |
|
plasma ebv dna |
11 |
|
promoter hypermethylation |
11 |
|
quality of life |
11 |
|
retrospective studies |
11 |
|
staging |
11 |
|
survival rate |
11 |
|
aged, 80 and over |
10 |
|
case-control study |
10 |
|
cognitive behavioral therapy |
10 |
|
family caregiver |
10 |
|
induction chemotherapy |
10 |
|
molecular tumour board |
10 |
|
next-generation sequencing |
10 |
|
oncology |
10 |
|
precision oncology |
10 |
|
recurrent |
10 |
|
recursive partitioning analysis |
10 |
|
sequence-directed therapy |
10 |
|
25-hydroxyvitamin d |
9 |
|
adc |
9 |
|
chromatin accessibility |
9 |
|
chromosome 6p |
9 |
|
cognitive behavioural therapy |
9 |
|
dce-mri |
9 |
|
dietary fiber |
9 |
|
dw-mri |
9 |
|
ebv |
9 |
|
family caregivers |
9 |
|
fresh vegetable and fruit |
9 |
|
genetic epidemiology |
9 |
|
genetic variant |
9 |
|
host-virus interaction |
9 |
|
illumina humanmethylation450 |
9 |
|
leucocyte telomere length |
9 |
|
life-course |
9 |
|
local recurrence |
9 |
|
male |
9 |
|
methylome |
9 |
|
milk |
9 |
|
mrs |
9 |
|
multiple imputation |
9 |
|
neoplasm staging |
9 |
|
npc risk |
9 |
|
preserved food |
9 |
|
prognostic factors |
9 |
|
prognostic marker |
9 |
|
reirradiation |
9 |
|
salvage treatment |
9 |
|
soybean product |
9 |
|
stage classification |
9 |
|
survival analysis |
9 |
|
survival prediction |
9 |
|
telomere biology |
9 |
|
toxicities |
9 |
|
treatment outcome |
9 |
|
ultraviolet radiation |
9 |
|
vitamin d |
9 |
|
vitamin d deficiency |
9 |
|
whole-genome bisulfite sequencing |
9 |
|
bintrafusp alfa |
8 |
|
breast cancer |
8 |
|
china |
8 |
|
cigarette smoking |
8 |
|
correlative biomarkers |
8 |
|
dose-response relation |
8 |
|
head and neck cancer |
8 |
|
nasopharyngectomy |
8 |
|
recurrent or metastatic nasopharyngeal cancer |
8 |
|
safety |
8 |
|
smoking cessation |
8 |
|
survival outcome |
8 |
|
toxicity |
8 |
|
treatment |
8 |
|
advanced cancer |
7 |
|
advanced lung cancer |
7 |
|
blm |
7 |
|
ccdc170 |
7 |
|
cognitive function |
7 |
|
concurrent chemotherapy |
7 |
|
covid-19 |
7 |
|
disease-free survival |
7 |
|
dna dsb repair |
7 |
|
dyspnea |
7 |
|
familial npc |
7 |
|
genetic susceptibility |
7 |
|
genomic adjusted radiation dose |
7 |
|
immunotherapy |
7 |
|
medical sciences |
7 |
|
meta-analysis |
7 |
|
nhej |
7 |
|
pathway associations |
7 |
|
personalize |
7 |
|
radiation dose |
7 |
|
screening |
7 |
|
sequence |
7 |
|
surgery |
7 |
|
tai chi |
7 |
|
tert |
7 |
|
adherens junctions - metabolism |
6 |
|
adolescent |
6 |
|
alpha b-crystallin |
6 |
|
anti-angiogenesis |
6 |
|
asian continental ancestry group |
6 |
|
autoimmune disease |
6 |
|
biomarker |
6 |
|
breast neoplasms |
6 |
|
cadherins - metabolism |
6 |
|
cancer immunosuppression |
6 |
|
carcinoma |
6 |
|
carcinoma - metabolism - pathology |
6 |
|
conservation |
6 |
|
cxcl8 |
6 |
|
cxcr2 |
6 |
|
dna methylation |
6 |
|
dnmt1 |
6 |
|
dosimetric predictors |
6 |
|
double-negative b cells |
6 |
|
drug resistance |
6 |
|
e-cadherin |
6 |
|
early diagnosis |
6 |
|
follow-up studies |
6 |
|
half-life clearance |
6 |
|
hong kong - epidemiology |
6 |
|
hypothyroidism |
6 |
|
latent transforming growth factor β binding protein 2 (ltbp-2) |
6 |
|
metastatic growth |
6 |
|
mif |
6 |
|
mortality |
6 |
|
ms‐hrm |
6 |
|
nasopharyngeal neoplasms - metabolism - pathology |
6 |
|
palbociclib |
6 |
|
palliative care |
6 |
|
patient-derived xenografts |
6 |
|
pattern of failure |
6 |
|
plasma epstein–barr virus deoxyribonucleic acid |
6 |
|
radiation therapy |
6 |
|
radiotherapy dosage |
6 |
|
risk factors |
6 |
|
saha |
6 |
|
second primary cancer |
6 |
|
staging system |
6 |
|
sulforaphane |
6 |
|
tai-chi |
6 |
|
tnm staging |
6 |
|
treatment outcomes |
6 |
|
tumor cell dormancy |
6 |
|
tumor suppression |
6 |
|
tumor suppressor proteins - metabolism |
6 |
|
tumour spheres |
6 |
|
wif1 |
6 |
|
β-catenin |
6 |
|
3' untranslated region |
5 |
|
adenocarcinoma - drug therapy - economics |
5 |
|
animal experiment |
5 |
|
animal model |
5 |
|
animal tissue |
5 |
|
antigen expression |
5 |
|
antineoplastic combined chemotherapy protocols - administration and dosage - economics - therapeutic use |
5 |
|
breast |
5 |
|
cancer outcomes |
5 |
|
cancer site-standardized relative survival |
5 |
|
cheung chau island |
5 |
|
cisplatin |
5 |
|
colorectal neoplasms - drug therapy - economics |
5 |
|
cross-border healthcare |
5 |
|
early detection |
5 |
|
esophageal cancer |
5 |
|
folinic acid |
5 |
|
functional assessment |
5 |
|
global health |
5 |
|
head and neck |
5 |
|
head and neck cancers |
5 |
|
health care costs - statistics and numerical data |
5 |
|
health economics |
5 |
|
health reform |
5 |
|
hospital authority |
5 |
|
igra |
5 |
|
immune checkpoint inhibitors |
5 |
|
immune regulation |
5 |
|
insurance, health, reimbursement - economics |
5 |
|
lymph node metastasis |
5 |
|
magnetic resonance imaging |
5 |
|
mastectomy, segmental |
5 |
|
medical records |
5 |
|
metabolic reprogramming |
5 |
|
metastatic |
5 |
|
metronomic |
5 |
|
multidisciplinary management |
5 |
|
nasophanrygeal carcinoma |
5 |
|
network meta-analysis |
5 |
|
nrf2 |
5 |
|
oral cyclophosphamide |
5 |
|
oxaliplatin |
5 |
|
oxidative phosphorylation |
5 |
|
policy review |
5 |
|
pooled analysis |
5 |
|
precision medicine |
5 |
|
prevalence |
5 |
|
re‐irradiation |
5 |
|
risk |
5 |
|
salvage |
5 |
|
single-cell sequencing |
5 |
|
societal perspective |
5 |
|
survivorship |
5 |
|
therapeutic evaluation |
5 |
|
tnm |
5 |
|
trade in healthcare services |
5 |
|
trends |
5 |
|
tuberculosis reactivation |
5 |
|
tumor microenvionment |
5 |
|
tumour board |
5 |
|
young adult |
5 |
|
ajcc/uicc staging system |
4 |
|
altered fractionation |
4 |
|
analysis of variance |
4 |
|
antitumor |
4 |
|
at13387 |
4 |
|
bioinformatics |
4 |
|
breast - anatomy & histology |
4 |
|
breast neoplasms - pathology - radiography - radiotherapy - surgery |
4 |
|
checkpoint inhibitors |
4 |
|
chi-square distribution |
4 |
|
combined modality therapy |
4 |
|
concurrent-adjuvant chemotherapy |
4 |
|
data mining |
4 |
|
dimensionality reduction |
4 |
|
dose-response relationship, radiation |
4 |
|
evi1 |
4 |
|
gastrectomy |
4 |
|
hsp90 inhibitor |
4 |
|
icg-001 |
4 |
|
immunohistochemistry |
4 |
|
intensity‐modulated radiotherapy |
4 |
|
local control |
4 |
|
machine learning |
4 |
|
mammography - psychology - utilization |
4 |
|
mastectomy, segmental - trends |
4 |
|
masticator space |
4 |
|
mir-449a |
4 |
|
mir-96 |
4 |
|
nasopharyngeal neoplasms - radiotherapy |
4 |
|
organ size |
4 |
|
radiation boost |
4 |
|
radiomics |
4 |
|
rapidarc |
4 |
|
risk assessment |
4 |
|
senescence |
4 |
|
systematic review |
4 |
|
therapeutic benefit |
4 |
|
tmn classification |
4 |
|
tnm staging system |
4 |
|
2-methoxyestradiol |
3 |
|
ace-27 |
3 |
|
age factors |
3 |
|
anti-pd therapy |
3 |
|
antineoplastic combined chemotherapy protocols - therapeutic use |
3 |
|
bcl-2/xl |
3 |
|
breast carcinoma |
3 |
|
breast conservation therapy |
3 |
|
breast neoplasms - epidemiology - genetics - pathology |
3 |
|
breast neoplasms - epidemiology - genetics - pathology - surgery |
3 |
|
breast neoplasms - mortality - surgery |
3 |
|
breast neoplasms - psychology |
3 |
|
breast neoplasms - radiography - surgery |
3 |
|
carcinoma - drug therapy - mortality - pathology - radiotherapy |
3 |
|
carcinoma - epidemiology - genetics - pathology - secondary - surgery |
3 |
|
carcinoma, ductal - epidemiology - genetics - pathology |
3 |
|
carcinoma, lobular - epidemiology - genetics - pathology |
3 |
|
carcinoma, squamous cell |
3 |
|
chemotherapy, adjuvant |
3 |
|
clinical application |
3 |
|
clinical target volume (ctv) |
3 |
|
co-morbidity |
3 |
|
cold tumor |
3 |
|
comorbidity |
3 |
|
concurrent chemoradiotherapy |
3 |
|
concurrent-adjuvant |
3 |
|
concurrent-adjuvant chemoradiotherapy |
3 |
|
cost-benefit analysis |
3 |
|
cranial nerve palsy |
3 |
|
cultural equivalence |
3 |
|
delineation |
3 |
|
do-not-resuscitate |
3 |
|
dose |
3 |
|
dose constraint |
3 |
|
dose escalation |
3 |
|
dose fractionation |
3 |
|
dose specification |
3 |
|
dose-response |
3 |
|
dosimetry |
3 |
|
drug therapy |
3 |
|
elderly |
3 |
|
end of life |
3 |
|
end-of-life care |
3 |
|
endoreduplication |
3 |
|
epidermal growth factor; stevens-johnson syndrome |
3 |
|
ercc1 |
3 |
|
familial |
3 |
|
familial risk |
3 |
|
feasibility studies |
3 |
|
fractionation |
3 |
|
functional assessment of cancer therapy-general (fact- g) |
3 |
|
gastric neoplasm |
3 |
|
gene amplification |
3 |
|
gene expression profiling |
3 |
|
genes, erbb-2 |
3 |
|
gross target volume (gtv) |
3 |
|
guideline |
3 |
|
hospice |
3 |
|
image-guidance radiotherapy |
3 |
|
in situ hybridization - methods |
3 |
|
in situ hybridization, fluorescence |
3 |
|
induction-concurrent |
3 |
|
international atomic energy agency (iaea) |
3 |
|
laser-enhanced immunotherapy |
3 |
|
levels of evidence |
3 |
|
liver |
3 |
|
liver neoplasms - psychology |
3 |
|
local failure |
3 |
|
low-middle income countries |
3 |
|
lung |
3 |
|
lung neoplasms - psychology |
3 |
|
lymphatic metastasis |
3 |
|
mammography |
3 |
|
mammography - economics |
3 |
|
markov chain model |
3 |
|
mastectomy |
3 |
|
mastectomy - statistics & numerical data |
3 |
|
mastectomy, modified radical |
3 |
|
models, statistical |
3 |
|
nasopharyngeal |
3 |
|
nasopharyngeal cancer (npc) |
3 |
|
nasopharyngeal neoplasms - drug therapy - mortality - pathology - radiotherapy |
3 |
|
nasopharyngeal neoplasms - drug therapy - mortality - radiotherapy |
3 |
|
nasopharyngeal neoplasms - epidemiology - mortality - pathology |
3 |
|
neoplasm recurrence, local |
3 |
|
neoplasm recurrence, local - radiography |
3 |
|
neoplasm staging - methods |
3 |
|
neoplasms - psychology |
3 |
|
nodal |
3 |
|
non-small-cell lung; receptor |
3 |
|
organ at risk |
3 |
|
pain control |
3 |
|
parapharyngeal space |
3 |
|
patient outcome assessment |
3 |
|
patient selection |
3 |
|
predictive |
3 |
|
prognostic factor |
3 |
|
psychometrics |
3 |
|
questionnaires |
3 |
|
radiotherapy access |
3 |
|
radiotherapy, adjuvant |
3 |
|
radiotherapy, conformal - methods |
3 |
|
randomized trial |
3 |
|
receptor, epidermal growth factor |
3 |
|
recommendation |
3 |
|
responsive drug release |
3 |
|
risk assessment - methods |
3 |
|
sensorineural hearing loss |
3 |
|
squamous cell carcinoma |
3 |
|
standard of care |
3 |
|
stat3/5 |
3 |
|
temporal lobe necrosis |
3 |
|
therapeutic index |
3 |
|
time |
3 |
|
treatment failure |
3 |
|
tumor control probability |
3 |
|
tumor metastasis |
3 |
|
accelerated radiotherapy |
2 |
|
adaptive planning |
2 |
|
adjuvant therapy |
2 |
|
artificial intelligence |
2 |
|
behavior change |
2 |
|
brain necrosis |
2 |
|
cancer survivor |
2 |
|
carcinoma - radiotherapy |
2 |
|
cervical metastases |
2 |
|
charged particle therapy |
2 |
|
clinical outcome |
2 |
|
cnvs |
2 |
|
contamination |
2 |
|
copy number variation |
2 |
|
covid‐19 |
2 |
|
differentiation |
2 |
|
dna repair |
2 |
|
docetaxel |
2 |
|
dosimetric parameters |
2 |
|
ductal carcinoma in situ |
2 |
|
epigenome |
2 |
|
epstein–barr virus |
2 |
|
excision repair cross complementation group 1 protein expression |
2 |
|
external beam radiotherapy |
2 |
|
extranodal extension |
2 |
|
family aggregation |
2 |
|
gemcitabine |
2 |
|
glottis |
2 |
|
head neck |
2 |
|
hepatocellular |
2 |
|
histological typing |
2 |
|
hypoglossal nerve |
2 |
|
hypothalamic-pituitary dysfunction |
2 |
|
hypothalamo-hypophyseal system - physiopathology - radiation effects |
2 |
|
image-guided radiotherapy |
2 |
|
indonesia |
2 |
|
induction |
2 |
|
induction-concurrent chemotherapy |
2 |
|
liver cancer |
2 |
|
liver neoplasm |
2 |
|
lung neoplasms |
2 |
|
m-pac |
2 |
|
methylation |
2 |
|
mhealth |
2 |
|
mutational landscape |
2 |
|
nasopharyngeal neoplasms - physiopathology - radiotherapy |
2 |
|
nasopharynx |
2 |
|
nasopharynx - cancer - chemotherapy. |
2 |
|
nasopharynx - cancer - radiotherapy. |
2 |
|
nasopharynx - cancer - treatment. |
2 |
|
nasopharyugeal carcinoma |
2 |
|
neoplasm recurrence |
2 |
|
non-keratinizing |
2 |
|
non-keratinizing carcinoma |
2 |
|
non-small-cell lung |
2 |
|
organs at risk |
2 |
|
otolaryngology |
2 |
|
particle therapy |
2 |
|
pemetrexed |
2 |
|
physical activity |
2 |
|
planning study |
2 |
|
prognostic value |
2 |
|
prostate cancer |
2 |
|
prostatic neoplasms - radiotherapy |
2 |
|
radiation dosimetry |
2 |
|
radiation injuries - pathology |
2 |
|
radiation-induced liver injury |
2 |
|
radioembolization |
2 |
|
radiometry - methods |
2 |
|
radiotherapy - adverse effects |
2 |
|
radiotherapy planning, computer-assisted |
2 |
|
radiotherapy planning, computer-assisted - methods |
2 |
|
reproducibility of results |
2 |
|
respiratory control |
2 |
|
retropharyngeal lymph node |
2 |
|
risk of contamination |
2 |
|
sensitivity and specificity |
2 |
|
signs and symptoms |
2 |
|
snvs |
2 |
|
socioeconomic factors |
2 |
|
software |
2 |
|
stereotaxic techniques |
2 |
|
stomach cancer |
2 |
|
svs |
2 |
|
temporal lobe - pathology - radiation effects |
2 |
|
time factors |
2 |
|
tumour suppressor genes |
2 |
|
undifferentiated carcinoma |
2 |
|
volumetric modulated arc therapy |
2 |
|
whole-genome sequencing |
2 |
|
*salvage therapy |
1 |
|
*stomach neoplasms |
1 |
|
adenocarcinoma/*secondary |
1 |
|
aggressive reirradiation |
1 |
|
antineoplastic combined chemotherapy protocols/*adverse effects |
1 |
|
associated regional/distant failures |
1 |
|
atherosclerosis |
1 |
|
atlas |
1 |
|
biological equivalent formulae |
1 |
|
biological equivalent formulas |
1 |
|
bone neoplasm |
1 |
|
bone tumour |
1 |
|
brachytherapy/*methods |
1 |
|
cancer patient |
1 |
|
cancer radiotherapy |
1 |
|
cancer surgery |
1 |
|
cancer therapy |
1 |
|
carcinoma/*drug therapy |
1 |
|
carcinoma/mortality/pathology/radiotherapy |
1 |
|
carotid stenosis |
1 |
|
cerebral necrosis |
1 |
|
cisplatin/administration & dosage |
1 |
|
clinical study design |
1 |
|
clinical trials |
1 |
|
cohort studies |
1 |
|
consensus |
1 |
|
consensus delineation guidelines |
1 |
|
conventional fractionation |
1 |
|
cumulative dose |
1 |
|
cutaneous t-cell lymphoma |
1 |
|
data collection |
1 |
|
de-escalation |
1 |
|
effective strategies |
1 |
|
elective neck radiotherapy |
1 |
|
endarterectomy, carotid |
1 |
|
extranodal lymphoma |
1 |
|
failure-free rates |
1 |
|
fatal outcome |
1 |
|
fluorouracil/administration & dosage |
1 |
|
genes, p53/genetics |
1 |
|
granulomatous slack skin |
1 |
|
gross tumour volume (gtv) |
1 |
|
head and neck neoplasms |
1 |
|
head and neck tumors |
1 |
|
health policy |
1 |
|
health systems |
1 |
|
hyperprolactinaemia |
1 |
|
immediate autologous breast reconstruction |
1 |
|
immunoglobulin g/analysis |
1 |
|
immunoglobulin kappa-chains/analysis |
1 |
|
immunoglobulin light chains/analysis |
1 |
|
in situ hybridization epstein-barr virus-encoded rna |
1 |
|
intensity modulated radiotherapy |
1 |
|
interobserver variability |
1 |
|
late complications |
1 |
|
late irradiation complications |
1 |
|
late radiation-induced complications |
1 |
|
late sequelae |
1 |
|
latency |
1 |
|
li-fraumeni syndrome/genetics/therapy |
1 |
|
local salvage |
1 |
|
long-term local control and survival |
1 |
|
long-term survival results |
1 |
|
lymph node levels |
1 |
|
maintenance therapy |
1 |
|
mandible |
1 |
|
mandibular osteoradionecrosis |
1 |
|
megavoltage radiation therapy |
1 |
|
melanoma/*secondary |
1 |
|
metastatic nasopharyngeal carcinoma |
1 |
|
mycosis fungoides |
1 |
|
myelinolysis, central pontine/*chemically induced |
1 |
|
n-staging systems |
1 |
|
nasopharyngeal carcinoma in situ |
1 |
|
nasopharyngeal neoplasm |
1 |
|
nasopharyngeal neoplasms/*drug therapy |
1 |
|
nasopharyngeal neoplasms/mortality/pathology/*radiotherapy |
1 |
|
nasopharynx -- cancer. |
1 |
|
neck nodes |
1 |
|
neoplasm recurrence, local/mortality/pathology/*radiotherapy/*surgery |
1 |
|
neoplasms, multiple primary/*genetics |
1 |
|
no elective whole neck irradiation |
1 |
|
nodal volume selection |
1 |
|
oncology services |
1 |
|
outcome |
1 |
|
ovarian neoplasms/*genetics |
1 |
|
paraganglioma |
1 |
|
parapharyngeal space tumors |
1 |
|
partial recovery |
1 |
|
patterns of relapse |
1 |
|
pedigree |
1 |
|
personalized medicine |
1 |
|
plasma cells/pathology |
1 |
|
plasmacytoma/*pathology |
1 |
|
post-mastectomy radiotherapy |
1 |
|
prediction of necrotic rates |
1 |
|
preinvasive lesions |
1 |
|
primary tumor volume |
1 |
|
probability of tumor control |
1 |
|
radiation oncology |
1 |
|
radiation-induced complication |
1 |
|
radiologic extranodal extension |
1 |
|
radiosurgery/*methods |
1 |
|
recurrence |
1 |
|
recurrent nasopharyngeal carcinoma |
1 |
|
resilience |
1 |
|
salvage surgery |
1 |
|
schwannoma |
1 |
|
skin neoplasms/*pathology |
1 |
|
skin/pathology |
1 |
|
soft-tissue sarcoma |
1 |
|
stage i (ho's classification) |
1 |
|
study management |
1 |
|
systemic therapy |
1 |
|
target delineation |
1 |
|
teeth extraction |
1 |
|
teratoma/*genetics |
1 |
|
testicular hydrocele/*etiology |
1 |
|
testicular neoplasms/*secondary |
1 |
|
thoracic neoplasms/*pathology |
1 |
|
total biological effect |
1 |
|
toxicity reduction |
1 |
|
treatment complications |
1 |
|
unperturbed tumor growth |
1 |
|
volume de-escalation |
1 |
|
waiting time |
1 |
|
worldwide consensus |
1 |
